Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Bezan, A; Posch, F; Ploner, F; Bauernhofer, T; Pichler, M; Szkandera, J; Hutterer, GC; Pummer, K; Gary, T; Samonigg, H; Beyer, J; Winder, T; Hermanns, T; Fankhauser, CD; Gerger, A; Stotz, M.
Risk stratification for venous thromboembolism in patients with testicular germ cell tumors.
PLoS One. 2017; 12(4):e0176283-e0176283
Doi: 10.1371/journal.pone.0176283
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Gerger Armin
- Terbuch Angelika
- Co-Autor*innen der Med Uni Graz
- Bauernhofer Thomas
- Gary Thomas
- Hutterer Georg
- Pichler Martin
- Posch Florian
- Pummer Karl
- Samonigg Hellmut
- Stotz Michael
- Szkandera Joanna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Patients with testicular germ cell tumors (TGCT) have an increased risk for venous thromboembolism (VTE). We identified risk factors for VTE in this patient cohort and developed a clinical risk model. In this retrospective cohort study at the Medical University of Graz we included 657 consecutive TGCT patients across all clinical stages. A predictive model for VTE was developed and externally validated in 349 TGCT patients treated at the University Hospital Zurich. Venous thromboembolic events occurred in 34 (5.2%) patients in the Graz cohort. In univariable competing risk analysis, higher clinical stage (cS) and a retroperitoneal lymphadenopathy (RPLN) were the strongest predictors of VTE (p<0.0001). As the presence of a RPLN with more than 5cm in greatest dimension without coexisting visceral metastases is classified as cS IIC, we constructed an empirical VTE risk model with the following four categories (12-month-cumulative incidence): cS IA-B 8/463 patients (1.7%), cS IS-IIB 5/86 patients (5.9%), cS IIC 3/21 patients (14.3%) and cS IIIA-C 15/70 patients (21.4%). This risk model was externally validated in the Zurich cohort (12-month-cumulative incidence): cS IA-B (0.5%), cS IS-IIB (6.0%), cS IIC (11.1%) and cS IIIA-C (19.1%). Our model had a significantly higher discriminatory performance than a previously published classifier (RPLN-VTE-risk-classifier) which is based on the size of RPLN alone (AUC-ROC: 0.75 vs. 0.63, p = 0.007). According to our risk stratification, TGCT patients with cS IIC and cS III disease have a very high risk of VTE and may benefit from primary thromboprophylaxis for the duration of chemotherapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Humans -
- Male -
- Neoplasms, Germ Cell and Embryonal - complications
- Neoplasms, Germ Cell and Embryonal - pathology
- Retrospective Studies -
- Risk Factors -
- Testicular Neoplasms - complications
- Testicular Neoplasms - pathology
- Venous Thromboembolism - etiology